f

Famotidine 20 mg vs ranitidine 150 mg

Famotidine 20 mg vs ranitidine 150 mg

How much famotidine equals 300 mg of ranitidine

In this prospective, double-blind study, 183 patients with endoscopically proven duodenal ulcers were randomly assigned to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2–8 weeks. The four classes had identical pretreatment characteristics. After 4 weeks of therapy, 38 of 42 (90.5%) of the famotidine-treated patients had healed with the 40 mg once nightly regimen, 35 of 42 (83.3%) with the 20 mg twice daily regimen, and 37 of 41 (90.2%) with the 40 mg twice daily regimen. In the ranitidine section, 40 out of 43 patients (93.0%) recovered. The results were 97.6, 95.2, 100, and 93.0 percent after 8 weeks of therapy. There were no statistically relevant differences between the famotidine and ranitidine classes. All of the therapies were well tolerated, and serious side effects were uncommon. Famotidine 40 mg given once at night appears to be as safe and effective as traditional ranitidine therapy, suggesting the significance of overnight gastric acidity in duodenal ulcer disease pathogenesis.

Famotidine equivalent to ranitidine

In this prospective, double-blind study, 183 patients with endoscopically proven duodenal ulcers were randomly assigned to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2-8 weeks. The four classes had identical pretreatment characteristics. After 4 weeks of therapy, 38 of 42 (90.5%) of the famotidine-treated patients had healed with the 40 mg once nightly regimen, 35 of 42 (83.3%) with the 20 mg twice daily regimen, and 37 of 41 (90.2%) with the 40 mg twice daily regimen. In the ranitidine section, 40 out of 43 patients (93.0%) recovered. The results were 97.6, 95.2, 100, and 93.0 percent after 8 weeks of therapy. There were no statistically relevant differences between the famotidine and ranitidine classes. All of the therapies were well tolerated, and serious side effects were uncommon. Famotidine 40 mg given once at night appears to be as safe and effective as traditional ranitidine therapy, suggesting the significance of overnight gastric acidity in duodenal ulcer disease pathogenesis.

Is pepcid an antihistamine

In this prospective, double-blind study, 183 patients with endoscopically proven duodenal ulcers were randomly assigned to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2–8 weeks. The four classes had identical pretreatment characteristics. After 4 weeks of therapy, 38 of 42 (90.5%) of the famotidine-treated patients had healed with the 40 mg once nightly regimen, 35 of 42 (83.3%) with the 20 mg twice daily regimen, and 37 of 41 (90.2%) with the 40 mg twice daily regimen. In the ranitidine section, 40 out of 43 patients (93.0%) recovered. The results were 97.6, 95.2, 100, and 93.0 percent after 8 weeks of therapy. There were no statistically relevant differences between the famotidine and ranitidine classes. All of the therapies were well tolerated, and serious side effects were uncommon. Famotidine 40 mg given once at night appears to be as safe and effective as traditional ranitidine therapy, suggesting the significance of overnight gastric acidity in duodenal ulcer disease pathogenesis.

Famotidine 20mg

The efficacy and safety of 20 mg famotidine nocte and 150 mg ranitidine h.s. for the prevention of duodenal ulcer recurrence were contrasted in a 24-week, double-blind, randomized study at 13 centers. An acute duodenal ulcer had been successfully treated in all participants with 40 mg famotidine nocte. Patients were endoscoped at baseline and 24 weeks, unless symptoms necessitated an earlier examination: of the 208 patients enrolled, 86 patients who received famotidine and 84 patients who received ranitidine met all protocol requirements and were deemed evaluable. Non-significant patterns in favor of famotidine were found in the intention to treat and per protocol analyses (P = 0.44 and 0.16, respectively). During the 24-week study period, 16.3% of the famotidine group and 25% of the ranitidine group experienced ulcer recurrence (95 percent confidence interval: -0.22 + 0.04). Day and night pain relief was recorded by 81.2 percent and 91.8 percent of famotidine-treated patients, respectively, after 24 weeks. In the ranitidine party, the figures were 73.5 percent and 85.5 percent, respectively. There were no laboratory anomalies linked to the study drugs, and only two drug-related adverse experiences (possibly or probably) were recorded, both in the famotidine community. The findings of this study support the conclusion that the efficacy of 20 mg famotidine nocte in preventing duodenal ulcer recurrence is comparable to that of ranitidine, with similar long-term tolerability.